Ruediger Rueger

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Isabelle Ray‐Coquard, Jean‐Yves Blay, Antoîne Italiano et al. · The Lancet Oncology · 2012 · 553 citations

Mdm2 Antagonist Rg7112, Medicine, Pharmacology +9

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Michael Andreeff, Kevin R. Kelly, Karen Yee et al. · Clinical Cancer Research · 2015 · 344 citations · Full text

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Maria Martinez‐García, Udai Banerji, Joan Albanell et al. · Clinical Cancer Research · 2012 · 151 citations

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Suzanne Leijen, Mark R. Middleton, Patricia Tresca et al. · Clinical Cancer Research · 2012 · 71 citations

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor

Sebastian Stahl, Ana Rita da Silva Mateus Seidl, Axel Ducret et al. · Proceedings of the National Academy of Sciences · 2015 · 54 citations · Full text